Physicians' Academy for Cardiovascular Education

How potassium binders can enable RAASi therapy in heart failure

Listen to the podcast
10' education - Oct. 11, 2022 - Prof. Mikhail Kosiborod, MD - Kansas City, MO, USA

Video navigation menu

  • Novel potassium binders 03:11
  • Efficacy data with patiromer 03:21
  • Efficacy data with sodium zirconium cyclosilicate (SZC) 10:13
  • Summary 14:56


Show transcript

Educational information

This lecture by Prof. Mikhail Kosiborod was part of the EBAC-accredited symposium "Clinical Case Discussion: The value of optimizing RAAS inhibition and preserving normokalemia in heart failure" held during the ESC congress 2022.


Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute. He is Professor of Medicine at the University of Missouri-Kansas City and the inaugural recipient of the Ben McCallister, MD Endowed Chair in Cardiovascular Research at Saint Luke’s Health System.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: